Insys
Sep 02, 2016
Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys; Insys marketed drug
Game changing agent, Opdivo, on a threshold to change standard of care in squamous cell carcinoma of the head and neck (SCCHN) According to Dr. Robert Ferris, who is vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
